Back A A A Font Size Receive E-mail Alerts Press Releases

Beflex Active Pacing Lead Family Approved in China

[2018-12-21] 

Clamart, France – December 19th, 2018 - MicroPort® CRM (a business unit of MicroPort Scientific Corporation), is pleased to announce that it has obtained regulatory approval of the Beflex active pacing lead family by the National Medical Products Administration in China.
 
Beflex is the first family of MicroPort® CRM leads in China, providing a full implantable cardiac pacing system when combined with the imported Reply or the domestic Rega pacemakers.
 
The Beflex active pacing lead has been widely utilized in other geographies, proving its safety over long term, with a 99.8% complication-free survival rate after eight years of implantation. Its flexible co-axial structure provides very good maneuverability in the heart chambers. Beflex features a pin-driven screw mechanism that facilitates fast lead tip positioning.
 
“The Chinese market is of primary importance to the growth of our CRM business,” commented Benoit Clinchamps, President of MicroPort® CRM. “The MicroPort Sorin CRM team in China has been extremely successful with the introduction of the Rega pacemaker, manufactured in China. I am confident that the team will continue to build on this momentum with the launch of the Beflex family of active pacing leads.”
 
“Our customers in China have been very pleased with the pacing technology that we have introduced over the past four years, but they have also requested us to provide them with full pacing systems,” added Li Wang, CEO of MicroPort Sorin CRM in China. “The Beflex leads are therefore a very welcome addition and crucial to further penetrate the Chinese market and ensure sustainable growth."

 

About MicroPort® CRM
 
Pioneering physiological therapies in cardiac rhythm management. Driven by our expert R&D teams and state-of-the-art manufacturing facilities across the globe, MicroPort® CRM conceives, designs and develops solutions for the management of cardiac rhythm disorders and heart failure. Headquartered in Paris, our precise technologies are manufactured in France, Italy, the Dominican Republic; and for the Chinese market, in China. MicroPort® CRM is part of MicroPort Scientific Corporation.
 
For more information visit www.crm.microport.com

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2019 MicroPort Scientific Corporation

CONTACT:
Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953
Email: ir@microport.com

 

[Prev]:Mr. Noboru Shimizu Joined MicroPort® CRM as Vice-President, Country Manager Japan, and Head of Commercial Operations of MicroPort® CRM Japan Co. Ltd.
[Next]:Experts from Pakistan Society of Interventional Cardiology Visits MicroPort®